GLP-1 agonists like Ozempic and Wegovy have become popular treatments for diabetes and obesity. Viking Therapeutics is trying to enter the weight loss market with VK2735, a dual GLP-1 and GIP receptor agonist. Despite promising clinical trials and some financial stability, the stock has skyrocketed, making it a high-risk opportunity.
It might be better to invest in established companies like Novo Nordisk.
